A shadow market for unlicensed slimming drugs is propelled by TikTok fitness influencers and vendors on communication apps, based on recent findings.
The experimental drug, which is still in research studies, is being promoted by online personalities for its alleged fat-burning properties. Followers are encouraged to message these accounts privately for supplier links, while also obtaining discount codes.
Separately, a robust trade exists on Telegram, where groups with numerous of participants share comparison images, injection guides and claims of next-day British shipping. Sellers promote the drug there before redirecting customers to WhatsApp for purchases.
This medication is an investigational injectable developed by American pharmaceutical company Eli Lilly. The treatment targets three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials suggest it could help patients lose up to a quarter of their body weight. Nicknamed the “triple G”, the drug is being hailed online as the successor to Ozempic.
However, physicians and chemists have cautions that the sale of what is still an unlicensed drug in the UK is a cause for concern and could result in users administering substances of unknown origin.
Several experts said the demand for retatrutide could be connected to the increasing price of licensed weight loss products such as Mounjaro.
Selling the unapproved drug on TikTok or messaging apps is prohibited in the United Kingdom, as it is an unapproved drug that must not be marketed or distributed for personal consumption under the British medical regulations.
Several influencers try to circumvent the regulations by calling to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled drug, but advertising and distribution can still breach pharmaceutical, advertising, and customer regulations, risking fines, legal action or prison.
According to the social media company, the platform has taken down violative material and banned associated hashtags and search suggestions. The organization stated it was committed to keeping the platform secure and investing in strengthening enforcement strategies.
Research also discovered groups with up to nine thousand participants selling retatrutide using Telegram's integrated discovery tool, which operates like a online catalog. Typing “retatrutide” instantly displays groups with numerous of users, populated with photos of weight loss, positive reviews and step-by-step instructions for preparing or administering at residence.
Within minutes of joining one group, a seller shared WhatsApp details, where the majority of purchases occur. The seller provided an instruction manual and promised delivery within 48 hours. When questioned whether the substance was genuine, one vendor responded: “You can’t be sure.” Another shared a image of a supposed testing documentation. Not one inquired about body mass, medical conditions or previous experience.
Inside these groups, posts show dark colored packages with Royal Mail stickers, claiming to include fresh supplies. One communication stated: “It took eight of us to load them this morning.”
Customers can choose between powder vials, prepared at home with purified liquid, or pre-filled pens typically priced at £160 for 20 milligrams. When questioned how long a injector should last, sellers give conflicting responses ranging from a several days to “depends on your body”.
A representative for the messaging service said it regularly monitored harmful material on its platform including content that encouraged the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.
“People are administering substances they cannot confirm. Even if the research behind this drug is valid, these digital products may not contain what they advertise,” said a pharmacy expert, the head of pharmacy at a pharmacy service.
A medical professional of an online medical service linked the increase in demand to current cost increases for approved slimming medications such as Mounjaro. “With costs increasing, patients are turning to social media. But fake treatments are highly risky. You can’t be certain what’s inside or whether the conditions they were produced in was clean,” she explained.
Her staff has previously seen patients harmed by personal administration from unverified sources. “We recognize the frustration, but buying from messaging apps or communication platforms is gambling with your health,” said Wyllie. “These materials could be contaminated or improperly measured.”
A representative from Eli Lilly stated the substance was in third stage clinical trials and had not been evaluated or authorized by any regulatory agency globally. “Consequently at this time no one can sell [it] for human use,” they said, noting that any product “misleadingly claiming itself as a Lilly investigational product not yet authorized … may expose users to possibly serious health risks”.
